-
Remdesivir (GS-5734): Mechanism and Evidence
2026-09-08
Remdesivir, also called GS-5734, is a monophosphoramidate prodrug that delivers a nucleoside analogue to viral RNA-dependent RNA polymerase. Cellular and animal data support its use as a research tool in coronavirus antiviral research and Ebola virus treatment research, while polymerase-structure evidence alone does not establish activity against Nipah virus.
-
L-Ornithine Workflows for Urea Cycle Research
2026-09-07
L-Ornithine supports controlled studies of OTC activity, ammonia disposal, and liver–brain metabolic signaling. This workflow-focused guide shows how to prepare the reagent, build metabolic enzyme assays, connect hepatic findings with astrocyte models, and troubleshoot solubility or interpretation problems.
-
HyperScript First-Strand cDNA Synthesis Kit for qPCR
2026-09-07
Turn difficult RNA inputs into actionable cDNA for PCR amplification and qPCR, including low-abundance bacterial transcripts and structured targets. This workflow shows how to select primers, tune reverse transcription, and reproduce the GlmS–sigB expression logic reported in Staphylococcus aureus biofilm research.
-
RepSox in iPSC Platelet Differentiation
2026-09-05
RepSox is a potent ALK5 inhibitor with a distinctive role in induced pluripotent stem cell reprogramming and TGF-β pathway research. This evidence-aware guide explains how to evaluate RepSox as a mechanistic variable in iPSC-derived platelet workflows without confusing validated findings with testable hypotheses.
-
Localized BDNF Release in Early NMJ Formation
2026-09-04
This study identifies muscle-cell podosome-like structures as spatial platforms that capture and release BDNF during the earliest stages of neuromuscular junction development. Using live imaging, targeted perturbations, and muscle-specific knockout mice, the authors show that activity-dependent BDNF trafficking and furin-mediated processing regulate aneural and subsequent synaptic acetylcholine receptor clustering.
-
Bufuralol Hydrochloride in β-Adrenergic Research
2026-09-04
Bufuralol hydrochloride is a non-selective β-adrenergic receptor antagonist with partial intrinsic sympathomimetic activity. Its documented cardiovascular pharmacology profile supports receptor-blockade, exercise-response, and tachycardia animal model studies, while hiPSC-derived intestinal organoids provide a separate human-relevant platform for absorption and metabolism research.
-
MnTBAP Chloride: Mitochondrial Stress Workflows
2026-09-03
MnTBAP Chloride provides a practical SOD-mimetic intervention for separating mitochondrial superoxide effects from downstream inflammation, energy failure, and cell injury. This workflow translates evidence from paraquat, inflammatory, and chronic-stress models into controlled assays with clearer dosing, sampling, and troubleshooting decisions.
-
S1PR3 Drives Neuronal Apoptosis After ICH
2026-09-03
The reference study identifies an S1P–S1PR3 mechanism that links acute intracerebral hemorrhage to TNF-α elevation, PI3K/AKT-associated signaling, and caspase-3-dependent neuronal apoptosis. Using mouse and HT22-cell models, the authors show that pharmacological S1PR3 inhibition reduces apoptotic markers and improves neurological outcomes, positioning S1PR3 as a candidate target for secondary brain injury research.
-
Aconitase Activity Assay in T-Cell Metabolism
2026-09-02
The Aconitase Activity Colorimetric Assay Kit provides a functional view of TCA-cycle integrity that complements studies of CD28–ARS2–PKM metabolic flexibility. This guide explains assay interpretation, oxidative damage measurement, controls, and translational limits.
-
Bufuralol hydrochloride in Organoid PK Studies
2026-09-02
Bufuralol hydrochloride combines broad β-adrenoceptor blockade with partial intrinsic sympathomimetic activity, making it useful for exposure, transport, and cardiovascular pharmacology workflows. This guide translates hiPSC-derived intestinal organoid findings into practical dosing, sampling, comparison, and troubleshooting strategies.
-
GDC-0941: A Mechanism-First Assay Guide
2026-09-01
GDC-0941 is a selective PI3K inhibitor for dissecting PI3K/Akt signaling, proliferation, and therapy resistance. This mechanism-first guide connects assay design with findings from pancreatic cancer research to improve interpretation beyond routine pathway inhibition workflows.
-
FGFR2 Fusion Targeting and Asparagine Depletion in ICC
2026-09-01
The reference study develops a cholesterol-conjugated DNA/RNA heteroduplex oligonucleotide that selectively suppresses the FGFR2-AHCYL1 fusion in intrahepatic cholangiocarcinoma. It also identifies an EGFR–STAT1–ASNS adaptation pathway and shows why asparagine depletion may strengthen fusion-directed treatment in preclinical models.
-
Cholesterol as a Design Variable in mRNA-LNP Assays
2026-08-31
Cholesterol is more than a structural lipid: it is a controllable variable in membrane biophysics, lipid metabolism research, and mRNA-LNP assay design. This article explains how to distinguish cholesterol-driven effects from broader formulation behavior using the recent intravesical p21 mRNA-LNP study as a translational case study.
-
Bufuralol Hydrochloride for Translational β-Blockade
2026-08-31
A translational framework for using Bufuralol hydrochloride to interrogate β-adrenergic biology, connect human iPSC-derived intestinal organoids with exposure science, and improve the interpretability of cardiovascular pharmacology research.
-
Annexin V-Cy5 Apoptosis Kit for Microglia
2026-08-30
The Annexin V-Cy5 Apoptosis Kit provides a rapid way to separate apoptosis-related changes from lysosomal dysfunction in microglia and other experimental models. Its 10-minute staining workflow supports both spatial fluorescence microscopy and quantitative flow cytometry apoptosis detection, making it useful for neuroimmunology, toxicology, and cancer research.